2 results
Approved WMOCompleted
To assess the efficacy of the co-administration of lanreotide Autogel 120 mg(administered via deep sub-cutaneous injections every 28 days) and pegvisomant(administered at 40 to 120 mg per week via sub-cutaneous injection given once ortwice a week)…
Approved WMOCompleted
The primary objective is to study protective antibody responses after SARS-CoV-2 vaccination in patients with pSS. Secondary objectives are monitoring of adverse events and disease activity after vaccination, studying the prognostic value of anti-…